(VIANEWS) - BioNTech SE (BNTX), China Petroleum & Chemical (SNP), eXp World Holdings (EXPI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. BioNTech SE (BNTX)
1145.1% sales growth and 133.85% return on equity
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases.
BioNTech SE's sales growth this year is expected to be 3227% and 4.1% for next year.
Year-on-year quarterly revenue growth grew by 12630.2%, now sitting on 7.77B for the twelve trailing months.
Volume
Today's last reported volume for BioNTech SE is 3325590 which is 2.24% below its average volume of 3401930.
BioNTech SE's sales growth is a negative 0% for the present quarter and 1145.1% for the next. The company's growth estimates for the ongoing quarter and the next is 1188.8% and 438%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 133.85%.
Volatility
BioNTech SE's last day, last week, and last month's current intraday variation average was 3.17%, 3.17%, and 5.97%, respectively.
BioNTech SE's highest amplitude of average volatility was 5.51% (day), 6.65% (last week), and 7.42% (last month), respectively.
BioNTech SE's Stock Yearly Top and Bottom Value
BioNTech SE's stock is valued at $344.06 at 05:22 EST, way under its 52-week high of $464.00 and way above its 52-week low of $80.55.
BioNTech SE's Moving Average
BioNTech SE's worth is way above its 50-day moving average of $269.93 and way higher than its 200-day moving average of $268.56.Previous days news about BioNTech SE(BNTX)
- According to Bloomberg Quint on Thursday, 2 December, "Children younger than 12 may also get access in coming weeks after European regulators cleared the shot from Pfizer Inc. and BioNTech SE for that age group."
- According to Bloomberg Quint on Thursday, 2 December, "They've already begun work to adapt their shots, with Pfizer Inc. and BioNTech SE saying they will be ready with a vaccine targeting omicron in 100 days, if necessary."
- According to Bloomberg Quint on Wednesday, 1 December, "The product from Pfizer Inc. and its partner BioNTech SE has been particularly in demand. "
2. China Petroleum & Chemical (SNP)
64.5% sales growth and 12.96% return on equity
China Petroleum & Chemical Corporation, an energy and chemical company, engages in oil and gas, and chemical operations in the People's Republic of China.
China Petroleum & Chemical's sales growth this year is expected to be 39.6% and 7% for next year.
Year-on-year quarterly revenue growth grew by 43.1%, now sitting on 2.33T for the twelve trailing months.
Volume
Today's last reported volume for China Petroleum & Chemical is 188843 which is 47.44% above its average volume of 128080.
China Petroleum & Chemical's sales growth for the next quarter is 64.5%. The company's growth estimates for the ongoing quarter and the next is 60.6% and 158%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.96%.
Volatility
China Petroleum & Chemical's last day, last week, and last month's current intraday variation average was 1.00%, 2.37%, and 1.64%, respectively.
China Petroleum & Chemical's highest amplitude of average volatility was 1.45% (day), 1.78% (last week), and 1.72% (last month), respectively.
China Petroleum & Chemical's Stock Yearly Top and Bottom Value
China Petroleum & Chemical's stock is valued at $0.00 at 05:22 EST, below its 52-week low of $42.92.
China Petroleum & Chemical's Moving Average
China Petroleum & Chemical's value is under its 50-day moving average of $49.02 and under its 200-day moving average of $50.66.3. eXp World Holdings (EXPI)
52.3% sales growth and 51.45% return on equity
eXp World Holdings, Inc. provides cloud-based real estate brokerage services for residential homeowners and homebuyers in the United States, Canada, the United Kingdom, Australia, South Africa, Portugal, France, Mexico, and India.
eXp World Holdings's sales growth this year is expected to be 93.4% and 34.1% for next year.
Year-on-year quarterly revenue growth grew by 182.8%, now sitting on 2.76B for the twelve trailing months.
Volume
Today's last reported volume for eXp World Holdings is 685200 which is 33.3% below its average volume of 1027390.
eXp World Holdings's sales growth for the next quarter is 52.3%. The company's growth estimates for the present quarter and the next is 10% and 100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.45%.
Volatility
eXp World Holdings's last day, last week, and last month's current intraday variation average was 2.92%, 2.70%, and 3.86%, respectively.
eXp World Holdings's highest amplitude of average volatility was 4.81% (day), 5.06% (last week), and 6.02% (last month), respectively.
eXp World Holdings's Stock Yearly Top and Bottom Value
eXp World Holdings's stock is valued at $40.82 at 05:22 EST, way under its 52-week high of $90.00 and way above its 52-week low of $22.52.
eXp World Holdings's Moving Average
eXp World Holdings's worth is below its 50-day moving average of $45.28 and below its 200-day moving average of $42.90.4. Helios Technologies (HLIO)
32.4% sales growth and 13.57% return on equity
Helios Technologies, Inc., together with its subsidiaries, develops, manufactures, and sells solutions for the hydraulics and electronics markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Helios Technologies's sales growth this year is expected to be 58.2% and 6.7% for next year.
Year-on-year quarterly revenue growth grew by 82%, now sitting on 803.12M for the twelve trailing months.
Volume
Today's last reported volume for Helios Technologies is 170686 which is 64.07% above its average volume of 104030.
Helios Technologies's sales growth for the next quarter is 32.4%. The company's growth estimates for the current quarter and the next is 58.5% and 35%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.57%.
Volatility
Helios Technologies's last day, last week, and last month's current intraday variation average was 4.13%, 2.05%, and 2.03%, respectively.
Helios Technologies's highest amplitude of average volatility was 4.97% (day), 2.91% (last week), and 3.14% (last month), respectively.
Helios Technologies's Stock Yearly Top and Bottom Value
Helios Technologies's stock is valued at $114.18 at 05:22 EST, below its 52-week high of $114.89 and way higher than its 52-week low of $47.69.
Helios Technologies's Moving Average
Helios Technologies's value is way above its 50-day moving average of $93.40 and way higher than its 200-day moving average of $79.61.5. United Therapeutics Corporation (UTHR)
10.5% sales growth and 13.99% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
United Therapeutics Corporation's sales growth this year is anticipated to be 12.9% and 10.3% for next year.
Year-on-year quarterly revenue growth grew by 23.3%, now sitting on 1.59B for the twelve trailing months.
Volume
Today's last reported volume for United Therapeutics Corporation is 585652 which is 56.97% above its average volume of 373092.
United Therapeutics Corporation's sales growth for the next quarter is 10.5%. The company's growth estimates for the current quarter and the next is a negative 7.3% and 63.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.99%.
Volatility
United Therapeutics Corporation's last day, last week, and last month's current intraday variation average was 1.60%, 1.29%, and 1.34%, respectively.
United Therapeutics Corporation's highest amplitude of average volatility was 3.91% (day), 2.62% (last week), and 2.81% (last month), respectively.
United Therapeutics Corporation's Stock Yearly Top and Bottom Value
United Therapeutics Corporation's stock is valued at $202.61 at 05:22 EST, under its 52-week high of $216.90 and way above its 52-week low of $129.43.
United Therapeutics Corporation's Moving Average
United Therapeutics Corporation's value is higher than its 50-day moving average of $194.96 and above its 200-day moving average of $189.42.6. Central Valley Community Bancorp (CVCY)
9.5% sales growth and 11.88% return on equity
Central Valley Community Bancorp operates as the bank holding company for the Central Valley Community Bank that provides various commercial banking services to small and middle-market businesses and individuals in the central valley area of California.
Central Valley Community Bancorp's sales growth this year is expected to be 13.6% and a negative 0.2% for next year.
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 84.78M for the twelve trailing months.
Volume
Today's last reported volume for Central Valley Community Bancorp is 16828 which is 10.1% below its average volume of 18720.
Central Valley Community Bancorp's sales growth for the next quarter is 9.5%. The company's growth estimates for the present quarter and the next is 54.3% and negative -8.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.88%.
Volatility
Central Valley Community Bancorp's last day, last week, and last month's current intraday variation average was 1.57%, 1.06%, and 0.63%, respectively.
Central Valley Community Bancorp's highest amplitude of average volatility was 2.84% (day), 1.66% (last week), and 1.59% (last month), respectively.
Central Valley Community Bancorp's Stock Yearly Top and Bottom Value
Central Valley Community Bancorp's stock is valued at $21.07 at 05:22 EST, way below its 52-week high of $23.83 and way higher than its 52-week low of $14.51.